Cariprazine (Vraylar): A drug for negative symptoms? Don’t be positive.
The Carlat Psychiatry Report, Volume 13, Number 11&12, November 2015
Talia Puzantian, PharmD, BCPP
Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.com
Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
On September 17, the FDA approved cariprazine (Vraylar) for the treatment of schizophrenia and bipolar disorder. There’s already some buzz about whether this medication has advantages over other atypicals for treating negative symptoms of schizophrenia.